x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

A view on

Discoveries in technology, medicine, and nutrition are emerging with accelerating speed and improving our health and quality of life. Brought to you by Lonza, “A View On” podcast is a series of short conversations with industry leaders. Join us to discuss new trends that are impacting scientific research, drug discovery and business. The series of monthly conversations with pharma, biotech and nutrition leaders from across industry and academia covers a wide range of topics from 3D bioprinting to

science life sciences

All Episodes

26:53

Episode 10: AI in the Pharma Industry

A view on ·

2022/08/31

Artificial Intelligence and Life Sciences: The Dawning of a Digital Revolution in Pharma Manufacturing Dr. Loubna Bouarfa, CEO of OKRA.ai, and Stephan Rosenberger, Lonza's Head of Digital Transformation, discuss how AI is currently transforming the pharma industry. Machine learning is an essential subset of the vast field of Artificial Intelligence, in which computer programs aim to mimic human intelligence. Machine learning is at work in many of the algorithms that impact our daily lives, from

en

25:06

Episode 9: De-risking Drug Development

A view on ·

2022/07/31

Where There’s A Risk, There’s A Way: De-risking Drug Development at the Earliest Stages Lonza’s wide array of analytical tools and professional experience create a go-to solution for small biotechs looking to decrease risk in their drug development process. An evolving toolbox of technology and advanced scientific knowledge is fueling the growth of a wide range of next-generation drugs in today’s pipelines. These novel but complex products, while offering the ability to treat previously unmet

en

24:30

Episode 8: Colors of Capsules

A view on ·

2022/06/20

Capsule Manufacturing: It’s Not Only What’s Inside That Counts The recent EU ban on Titanium Dioxide and changing customer habits are shaking up capsule production. Over the past few years, the coloring and manufacturing of pill capsules have undergone significant changes due to new EU regulations and customer demand for natural ingredients. And while originally invented to mask and protect the contents inside a capsule, research suggests that the color of a tablet or pill can affect how patients

en

19:17

Episode 7: Antibody-Drug Conjugates

A view on ·

2022/05/02

Antibody-drug Conjugates: Next-Generation of Targeted Cancer Treatments Iwan Bertholjotti and Laurence Bonnafoux from Lonza give an insider look at how these promising treatments make it from development to commercialization. Chemotherapy is the first-line treatment for most types of cancer. However, one of the major challenges with this approach is that it targets both cancer and healthy cells, with patients suffering severe side effects. A new class of therapies, called antibody-drug conjugates,

en

22:33

Episode 6: Manufacturing of Exosomes

A view on ·

2022/03/14

Putting Manufacturing First: Codiak Moves Swiftly into Clinical Trials with Exosome-based Treatments Sriram Sathyanarayanan, Codiak’s CSO, and Linda Bain, their CFO, share how the company moved into clinical trials in under 6 years. Exosomes, extremely small vesicles shed by all cell types, promise to become a viable delivery system for treatments of many diseases. But until recently, manufacturing them at a commercially viable scale has been unfeasible. That is why in 2015 the company Codiak

en

12:16

*Repost* Exosomes

A view on ·

2022/03/09

In this reposted episode from December 2020, we're exploring how a better understanding of exosomes is leading to new treatments and diagnostic technologies with Uwe Gottschalk. According to Uwe, the exosome revolution is already in full march. As researchers begin to identify how these cell-generated, nano-sized delivery drones function in the human body, novel drug delivery prospects are emerging, including applications for cancer, neurodegenerative diseases and spinal cord injury recovery

en

18:41

Episode 5: Importance of Immunogenicity

A view on ·

2021/12/20

De-risking Drug Development: Early Testing for Toxicity Saves Time and Resources Yvette Stallwood, head of Lonza’s Early Development Services, talks about patient safety and other advantages of early testing for immunogenicity in the drug development pipeline. In the high-stakes drug discovery game, from IND filings all the way up through the clinical trial phase, regulatory authorities are now expecting developers to have an immunogenicity risk strategy in place. “It really is essential that

en

06:55

Episode 4: Microbiome

A view on ·

2021/11/25

Host and Health: Tailoring Personalized Medicine Using The Unique Microbiome Fingerprint Professor Eran Elinav from the Weizmann Institute of Science discusses how the interaction between the microbiome and its host is transforming personalized medicine. “I believe that in the next five to ten years, exploiting the potential of the microbiome will be central to personalized and precision medicine,” explains Eran Elinav. His research into this second genome in the human body at the Weizmann

en

24:36

Episode 3: Antibody Biopolymer Conjugates for...

A view on ·

2021/10/20

Bridging Business and Biotechnology: Kodiak Sciences Is Increasing Treatment Efficacy for Retinal Diseases Victor Perlroth, MD, the Chairman and CEO of Kodiak Sciences, discusses how the company’s ABC platform medicines are designed to treat the leading causes of blindness. Age-related macular degeneration (AMD) is one of the leading causes of blindness in adults worldwide. This disease deteriorates the macula, a miraculous little spot on your retina that allows for precise vision in good light

en

18:54

Episode 2: Horseshoe crabs and recombinant factor C

A view on ·

2021/09/06

Safe Jabs Thanks to Horseshoe Crabs: Making Sure Your Injection is Free of Endotoxins Allen Burgenson, Lonza’s expert for all things testing, speaks to us about the dangers of endotoxin contamination and the future of non-animal testing for it. “Before testing for endotoxins in the 1940s, a physician literally had to gauge the risk to your life because of something called injection fever,” explains Allen Burgenson. Luckily, we’ve come a long way since then. Thanks to advanced testing methods, one

en

19:52

Episode 1: Oncolytic viruses

A view on ·

2021/08/02

A Welcome Virus: Cracking the Viral Code for the Battle Against Cancer Chairman and founder of PsiVac, Prof. Ghassan Alusi, and the chief operating officer, Imad Mardini, discuss how the company’s proprietary oncolytic virus platform offers new hope for cancer patients. During a time when everyone actively fears viruses (especially THE virus) and their mutations, it is only cancer cells that have cause to worry about oncolytic viruses, and rightly so. These mutated viruses are administered directly

en

07:29

Episode 11: Season 1 recap

A view on ·

2021/05/21

It’s the season finale for A View On, the Lonza podcast. Over the past 12 months of our initial run, we have brought you a series of conversations exploring the new pharma and biotechnology trends. We spoke to Lonza and the industry experts and discussed exciting topics, such as exosomes, stem cells, drug product testing, bioprinting, and much more. In the latest episode, the podcast host, Lonza’s Martina Ribar Hestericová, recaps the highlights from this season and looks forward to later this year

en

06:33

Episode10: Phage Therapy

A view on ·

2021/03/30

Devouring Bacteria: How Phage Therapy Is Shaping Antibacterial Treatments of the Future In this episode we speak with the CEO of BiomX, Jonathan Solomon, about producing and using phages to test and treat various diseases and conditions. Until very recently, treating a condition such as acne with an army of microscopic bacteria-destroyers known as phages—bacterial viruses that target and kill specific bacteria—would have seemed highly unlikely. However new research linking acne to an imbalance in

en

16:35

Episode 9: Streamlining the cell and gene therapy...

A view on ·

2021/02/24

Delivering Personalized Therapies: Streamlining the Supply Chain for a New Generation of Treatments In this episode, we speak with Amy DuRoss, Co-Founder and Chief Executive Officer of Vineti, about the challenges facing "just-in-time" manufacturing and delivery of personalized therapies—and the solutions her digital startup provides. According to Amy DuRoss, the COVID-19 vaccine distribution has exposed existing deficiencies in the entire pharmaceutical supply chain. This situation echoes,

en

12:16

Episode 8: Exosomes

A view on ·

2020/12/16

Exosomes Know Where To Go: Using the Body's Own Cell-to-Cell Communication Network for Diagnostics and Drug Delivery We speak with Uwe Gottschalk, the Chief Scientific Officer of Lonza, about how a better understanding of exosomes is leading to new treatments and diagnostic technologies. According to Uwe Gottschalk, the exosome revolution is already in full march. As researchers begin to identify how these cell-generated, nano-sized delivery drones function in the human body, novel drug delivery

en

08:37

Episode 7: Microbiome

A view on ·

2020/11/25

Bugs as Drugs: Harnessing the Therapeutic Potential of the Microbiome Lukas Schüpbach, the CEO of Bacthera, and Gemma Henderson, Bacthera’s Head of Project and Portfolio Management, speak to Lonza about creating pharmaceuticals from the human microbiome. The human microbiome, comprised of trillions of bacteria, fungi, viruses, and archaea, is unique to each individual and develops over the course of lifetime, stabilizing once we reach adulthood. Despite the widespread understanding that this

en

10:25

Episode 6: Gene editing

A view on ·

2020/10/15

Since the arrival of Crispr in 2009, gene editing has made its way into labs. Its groundbreaking importance was acknowledged through the 2020 Nobel Prize in Chemistry. Expanding gene editing for medical treatments, Cellectis focuses its 20 years of experience on developing cancer immunotherapies. Curious to Know More? Cellectis CEO André Choulika explains the technology of allogenic gene editing they invented in this episode of the podcast "A View On."

en

10:07

Episode 5: Therapy administration and its safety

A view on ·

2020/09/21

In 2016 Lonza established its Drug Product Services (DPS) to realize this supply chain model for its partners and clients. Since then the DPS has grown to a workforce of over 250 experienced experts focused on safety, efficacy and quality. To ensure that Lonza’s pharmaceuticals perform as expected in real-world situations, the DPS team simulates the entire administration process until certain the patient will receive the correct dose of the highest quality.

en

08:30

Episode 4: Cannabinoid science

A view on ·

2020/08/20

Cannabinoids are emerging as a treatment option for autoimmune and other immune-related diseases thanks to their modifications as synthetic derivatives. Emerald Health Pharmaceuticals has widened the potential application of cannabinoids by designing cannabidiol and cannabigerol derivatives that have a greater effect on the endocannabinoid system and can interact with receptors and pathways from other biosystems. Alain Rolland, COO of EHP, talks about using cannabinoids for unmet medical needs.

en

09:38

Episode 3: Mesenchymal stem cells for COVID-19 treatment

A view on ·

2020/07/19

Mesoblast CEO Dr. Silviu Itescu speaks to Lonza about the company’s advanced portfolio of anti-inflammatory allogeneic cellular medicines including remestemcel-L, which is currently being evaluated in a U.S. Phase 3 randomized controlled trial for acute respiratory distress syndrome (ARDS), the principal cause of mortality due to COVID-19 infection.

en

42 results

Similar Podcasts

X Minus 1 - Old Time Radio Show

Inception Point Ai

Science, Spoken

WIRED

This Week in Space (Audio)

TWiT

DarshanTalks Podcast

Darshan Kulkarni

The Best of Coast to Coast AM

iHeartPodcasts and Coast to Coast AM